OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension studyECCO'20 Vienna 2020
1
OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scoresECCO'20 Vienna 2020
1
OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida RegistryECCO'20 Vienna 2020
1
OP31: Meta–omics reveals microbiome driven proteolysis as a contributing ractor to severity of Ulcerative Colitis disease activityECCO'20 Vienna 2020
1
OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosaECCO'20 Vienna 2020
1
OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel DiseaseECCO'20 Vienna 2020
1
OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic studyECCO'20 Vienna 2020
1
OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel DiseaseECCO'20 Vienna 2020
1
OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s Disease – A multicenter randomized controlled trialECCO'20 Vienna 2020
1
OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epitheliumECCO'20 Vienna 2020
1
Optimal management of patient with severe Crohn’s disease treated with anti-TNF agents (Case presentation)18th IBD Intensive Advanced Course 2020
1
Pandora's box: Compilation of complicated situations in laparoscopic CD9th S-ECCO IBD Masterclass 2020
1
Pathogenesis, pathology and management of serrated lesions in IBD and non-IBD (Tandem talk)5th H-ECCO IBD Masterclass 2020
1